Meridian clinical Research, LLC

Omaha, Nebraska 68314

0 studies enrolling now · 58 studies all time

What they study most

Adverse Effects in the Use of the OsteoProbe System, Anthrax, Atrial Fibrillation, Axillary Hyperhidrosis, Back Pain Lower Back Chronic, Benign Prostatic Hypertrophy, COPD, COVID-19, Clostridium Difficile Associated Disease, Clostridium Difficile Infection, Cough, Cow Milk Allergy

Studies at this site

• VELOCITY: An Anthrax Vaccine Clinical Study — Completed
• Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals — Completed
• Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older — Completed
• Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection — Completed
• Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study — Completed
• A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older — Completed
• A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults — Completed
• Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302) — Completed
• Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age — Completed
• A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age. — Completed
• Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age — Completed
• Open Label Safety Study in Acute Treatment of Migraine — Completed
• Safety and Efficacy Study in Adult Subjects With Acute Migraines — Completed
• Clostridium Difficile Vaccine Efficacy Trial — Completed
• Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure — Completed
• Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age — Completed
• A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults — Completed
• Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2 — Completed
• Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age — Completed
• Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults — Running, not enrolling
• Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults — Completed
• A Phase 2 Study to Evaluate Immune Responses of FluMist® — Completed
• Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6-59 Months of Age — Completed
• A Study of Tanezumab in Adults With Chronic Low Back Pain — Completed
• Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine — Completed
• Dextromethorphan Pediatric Acute Cough Study — Stopped early
• Open Label Study Using OsteoProbe System — Completed
• Long Term Safety Study of Tanezumab in Chronic Low Back Pain — Stopped early
• GLORIA-AF Registry Program - Second and Third Phases — Completed
• A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years — Completed
• A Growth and Hypoallergenicity Study of a New Formula for Infants With Cow Milk Allergy — Completed
• Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults — Completed
• Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults — Completed
• Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults — Completed
• A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age — Completed
• Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms — Completed
• Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults — Completed
• Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine — Completed
• Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine — Completed
• A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects — Completed
• A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age — Completed
• A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine. — Completed
• Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults. — Completed
• A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years — Completed
• Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children — Completed
• Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain — Completed
• Efficacy and Safety of Diclofenac Sodium Gel in Hand Osteoarthritis — Completed
• Study of NXN 188 for the Treatment of Migraine With Aura — Completed
• Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain — Stopped early
• Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015 — Stopped early